Abbott, a leader in diabetes tech with one of the biggest lines of continuous glucose monitors, announced this week that it's ...
We like that management has turned its attention to new sources of growth. In our view, Abbott's FreeStyle Libre blood glucose monitor franchise is one of the most compelling innovations the firm ...
Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.
Zacks.com on MSN6d
Reasons to Retain ABT Stock in Your Portfolio NowInvestors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.
Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...
Argus analyst David Toung raised the firm’s price target on Abbott (ABT) to $150 from $145 and keeps a Buy rating on the shares. Abbott’s ...
Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device to empower people in improving overall health and wellness.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback